Medical research and development (R&D) differs from other R&D because of a unique linkage between output and input markets for medical products: potential consumers of existing medical products are also potential subjects in clinical trials required to develop new products. Therefore, an increase in the quality or reduction in the price of an existing treatment reduces the incentive of patients to participate in trials of new treatments. We provide evidence of this linkage, which we label the “subject supply effect,” by showing that a breakthrough HIV/AIDS treatment led to a sharp drop in the supply of trial subjects after the introduction of the treatment in 1996. The subject supply effect has important positive implications for how policies such as recent insurance expansions affect the rate of medical R&D and normative implications for whether subjects ought to be compensated for enrolling in clinical trials, an ethically controversial practice.

More on this topic

BFI Working Paper·Mar 10, 2025

The Rise of Healthcare Jobs

Joshua Gottlieb, Neale Mahoney, Kevin Rinz, and Victoria Udalova
Topics: Employment & Wages, Health care
BFI Working Paper·Feb 18, 2025

Economic Shocks and Healthcare Capital Investments

Michael R. Richards, Maggie Shi, and Christopher M. Whaley
Topics: Health care
BFI Working Paper·Jan 22, 2025

Network Rewiring and Spatial Targeting: Optimal Disease Mitigation in Multilayer Social Networks

Ozan Candogan, Michael D. König, Kieran Marray, and Frank W. Takes
Topics: Health care